Where does Aligos Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aligos Therapeutics, Inc. ranks #9,428 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aligos Therapeutics, Inc. hold?

Aligos Therapeutics, Inc. holds 33 US utility patents granted between 2021 and 2025, spanning 9 technology areas.

What is Aligos Therapeutics, Inc.'s Innovation Score?

Aligos Therapeutics, Inc. has an Innovation Score of 56.7 out of 100 (top 6% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aligos Therapeutics, Inc. focus on?

Aligos Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 29 patents, ranking #678 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Aligos Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Aligos Therapeutics, Inc..

What does claim depth mean for Aligos Therapeutics, Inc.'s patents?

Aligos Therapeutics, Inc.'s patents average 23.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aligos Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Aligos Therapeutics, Inc.

USPTO PatentsView assignee record - 33 granted patents across 9 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aligos ranks #9,428 of 49,997 tracked US assignees by granted-patent volume, with 33 patents across 9 technology areas.

#9,428
of 49,997 US assignees by volume: Top 6%
by Innovation Score (56.7/100): 23.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R9428 · US Corporation #9,428 · 33 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 33 grants
UPPER-Q #9,428/49,997
PHOTO-FINISH Agriculture…
CPC-NARROW A61P · 9 areas
INNOV-PAR 56.7/100
CLAIMS-DENSE 23.2 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Agriculture Victoria Services PTY Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aligos’s 56.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.2 pts (22%) Velocity 20.0 pts (35%) Breadth 10.6 pts (19%) Claim depth 13.9 pts (25%)

Qualcomm Incorporated · highest

85
Sikorsky Aircraft · near

57
Teledyne Flir · near

57
Aligos Therapeutics · this assignee

57
Hach · near

57
Universite De… · near

57
3D Lighting… · lowest

7

What this shows Aligos's Innovation Score is 56.7/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aligos?

Each dot is one of Aligos’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aligos’s own 23.2 claims/patent is ABOVE the 17.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aligos vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aligos's grants concentrate

Aligos Therapeutics, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 87.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (13 grants) versus a trough of 2 in 2022. By volume, Aligos sits between Agriculture Victoria Services PTY Ltd and Aragon Pharmaceuticals, Inc..

Aligos's three-year grant acceleration

Aligos Therapeutics, Inc. shows 24 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Agriculture Victo…

33
Ai Cure

33
Aircraft Medical

33
Albany Engineered…

33
Almirall

33
Altia Systems

33
Appdynamics

33
Aragon Pharmaceut…

33
Aligos Therapeuti… ◀

33

What this shows Aligos holds 33 patents at rank #9,431, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aligos

By rank, the assignees closest to #9,431 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aligos's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Aligos, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Aligos ranks #678 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (57 here).

Hach Company 57 Universite De Montpellier 57 Sikorsky Aircraft Corporation 57 Teledyne Flir, LLC 57

Aligos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

57 Top 6% higher than 94% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Aligos Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	6	18.2%
2022	2	6.1%
2023	13	39.4%
2024	9	27.3%
2025partial year	3	9.1%

Which technologies does Aligos Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 29

C07D - Heterocyclic Compounds 26

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 25

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C07C - Acyclic OR Carbocyclic Compounds 1

C12Y - Enzymes 1

C07K - Peptides 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aligos Therapeutics, Inc.'s patent record in context - here's where to go next.

Aligos Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #9,428 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aligos Therapeutics, Inc. against Agriculture Victoria Services PTY Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 56.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.